Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBsAg-guided optimized treatment for HBeAg-negative chronic hepatitis B
ChiCTR1800017019Phase 4Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of entecavir and pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: HBsAg. Started Aug 2018; status: recruiting.
02
Drugs
entecavirpegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1800017019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017019.